|
TMX2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.91402449445377E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.33949551240198E-11 |
| Normal-vs-Stage2 |
8.081800E-02 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62458935193399E-12 |
| Stage1-vs-Stage2 |
9.70409999999644E-05 |
| Stage1-vs-Stage3 |
2.255100E-03 |
| Stage1-vs-Stage4 |
5.87960000000276E-05 |
| Stage2-vs-Stage3 |
1.17789999976026E-08 |
| Stage2-vs-Stage4 |
1.54689999698476E-08 |
| Stage3-vs-Stage4 |
1.816560E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.99840144432528E-15 |
| Normal-vs-AfricanAmerican |
4.413000E-04 |
| Normal-vs-Asian |
3.26979998632737E-09 |
| Caucasian-vs-AfricanAmerican |
3.560800E-01 |
| Caucasian-vs-Asian |
3.208000E-01 |
| AfricanAmerican-vs-Asian |
8.694600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.15254505728535E-13 |
| Normal-vs-Female |
5.33828536930514E-12 |
| Male-vs-Female |
4.819900E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.85784762310959E-12 |
| Normal-vs-Age(41-60Yrs) |
7.31892324523642E-12 |
| Normal-vs-Age(61-80Yrs) |
3.82159970335749E-10 |
| Normal-vs-Age(81-100Yrs) |
3.99960000000421E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.030200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.912400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.683800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.134800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.973200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.401800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.80499981417404E-10 |
| Classical-VS-Follicular |
2.22449999975893E-07 |
| Classical-VS-Other |
5.651400E-01 |
| Classical-VS-Normal |
1.62458935193399E-12 |
| Tall-VS-Follicular |
1.62492241884138E-12 |
| Tall-VS-Other |
2.903200E-01 |
| Tall-VS-Normal |
1.62447832963153E-12 |
| Follicular-VS-Other |
4.487700E-02 |
| Follicular-VS-Normal |
3.185900E-02 |
| Other-VS-Normal |
1.794330E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.12520004003881E-09 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
1.14999999523135E-08 |
|
|
